OREANDA-NEWS. April 29, 2015. Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, announced today that it has received a CE Mark for a new ReCell device for the treatment of burns. This enhanced ReCell product offers treatment of up to a 1,920cm2 surface area; a 6-fold greater coverage than previously possible from the first generation product. The original ReCell device, covering 320cm2, allowed clinicians to treat only approximately 1.5% of an adult's total body surface area (TBSA). With the new device, ReCell is better aligned to meet grafting requirements of burn victims.

"This CE Mark approval represents an important step in realizing the full potential of Avita's best-in-class regenerative product portfolio. ReCell is now better positioned to address the needs of the burn patients and we look forward to commencing commercial activities across Europe, and a corresponding uptick in revenue," commented Adam Kelliher, Chief Executive Officer of Avita Medical.

The CE Marking is a legally-required mark for a product that is intended for sale in the European Market and declares that the product complies with the essential requirements of the relevant European health, safety and environmental protection legislation.